HDFC Mutual Fund acquired 13.90 lakh shares worth ₹235.6 crore in Entero Healthcare Solutions through a block deal at ₹1,695 per share on Friday. According to NSE data, the fund house purchased the entire stake from Prasid Uno Family Trust, which sold the shares in two separate transactions - 12.21 lakh shares and 1.68 lakh shares at the same price point. This transaction represents approximately 3.19% of the company's equity based on the June 30 shareholding base, with the stock settling at ₹1,732.30 on September 18, up 3.94% from the previous close of ₹1,666.60. The counter traded between ₹1,669.90 and ₹1,737.80 during the session. Public shareholder Surbhi Singh, through Prasid Uno Family Trust, was the seller in the transaction. The trust is the family-owned investment vehicle of Medlife co-founder Tushar Kumar.
The block deal significantly reduces Prasid Uno Family Trust's holding in Entero Healthcare Solutions, which held 45.50 lakh shares, representing 10.45% of the company as of June 30, 2026, according to BSE shareholding data. With Friday's transaction, the trust has sold 32.18 lakh shares during the September quarter, equivalent to a 7.39% stake, against its 10.45% holding. This latest transaction follows the trust's earlier stake sales, including the 1.7% stake sold in September worth ₹125.3 crore and 10.88 lakh shares sold on August 24. The company maintains a market capitalization of ₹7,539.50 crore on the NSE, with shares having touched a 52-week high of ₹1,920 on September 8 and a 52-week low of ₹944 recorded on December 29, 2025. The stock remains under the Additional Surveillance Measure (ASM) framework on the BSE.
Entero Healthcare Solutions, incorporated in 2018, operates as a healthcare products distributor in India with a technology-driven platform providing distribution services to pharmacies, hospitals and clinics across the country. The company connects healthcare-product manufacturers with healthcare providers through its integrated distribution network, enabling pharmacies, hospitals and clinics to access a broad range of healthcare products. The company's latest financials show total income of ₹1,943.50 crore with EBIT of ₹87.69 crore and PAT of ₹38.16 crore for the year ending March 2026. The stock's PE ratio stands at 60.1 and PB ratio at 4.3, with the company showing strong operational efficiency as it spent less than 1% of operating revenues towards interest expenses and 3.72% towards employee costs.
According to reports, Authum Investment & Infrastructure acquired 50.29 lakh shares for ₹176.17 crore at ₹350.25 per share in Karamtara Engineering, the renewable energy and transmission products manufacturer. The shares were acquired at ₹350.25 per share, with Karamtara Engineering shares also attracting strong buying interest, rising 38.6 percent to ₹352 from the issue price of ₹254 on their debut day. Additionally, BofA Securities Europe SA acquired 1.5 lakh shares for ₹42.4 crore at ₹2,826.6 per share in Gland Pharma from North Rock SG VCC, with Gland Pharma shares rallying 2.87 percent to ₹2,907.8. Meanwhile, State Street Global Advisors sold 37.32 lakh shares for ₹11.13 crore at ₹29.83 per share in Sigachi Industries through the SPDR Portfolio Emerging Markets ETF, while Croll Reynolds International sold 1.5 lakh shares for ₹3.91 crore at ₹261.07 per share in Mazda.
